Semaglutide

Drug Profile

Semaglutide

Alternative Names: NN-9535; NN-9536; NNC-0113-0217

Latest Information Update: 24 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novo Nordisk
  • Developer Novo Nordisk; Zosano Pharma
  • Class Antihyperglycaemics; Glucagon-like peptides
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Type 2 diabetes mellitus
  • Phase II Non-alcoholic steatohepatitis; Obesity

Most Recent Events

  • 24 Sep 2017 Novo Nordisk plans a phase I trial in Healthy volunteers in China (NCT03288740)
  • 28 Aug 2017 Phase-III clinical trials in Type-2 diabetes mellitus (Adjunctive treatment) in Taiwan, South Korea, China, Brazil (SC) (NCT03061214)
  • 28 Aug 2017 Novo Nordisk initiates enrolment in a phase III trial in Type-2 diabetes mellitus (Adjunctive treatment) in Hong Kong, South Africa, Ukraine (SC) (NCT03061214)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top